Tau Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of tau protein pathology in the living brain1. tau protein, which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of Alzheimer's Disease and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms2.
The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging Amyloid-Beta plaques. The first generation of tau PET tracers included:
Tau PET tracers bind to:
Ideal tau PET tracers should have:
Tau PET helps distinguish between:
Tau PET follows the Braak staging of tau pathology:
Tau PET is essential for:
In AD, tau deposition follows a characteristic pattern:
Different tracers show varying binding to:
Tau PET is crucial for:
Research continues on:
The study of Tau Pet Imaging In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1 Mintun MA, et al. FLORTauCIPIR (F 18 AV-1451) PET imaging in Alzheimer's Disease. Radiology. 2020;295(1):160-169.
2 Scholl M, et al. PET Imaging of tau pathology in Alzheimer's Disease. J Nucl Med. 2016;57(10):1531-1537.
3 Fleisher AS, et al. Phase 3 trial of flortaucipir for detecting Alzheimer's Disease tau pathology. Ann Nucl Med. 2020;34(4):234-245.
4 Villemagne VL, et al. Tau imaging: Early history and future directions. J Prev Alzheimers Dis. 2018;5(2):233-247.
5 Bejanin A, et al. Tau pathology and neurodegeneration in Alzheimer's Disease. Brain. 2017;140(9):2286-2294.
6 Sepulveda-Falla D, et al. Tau PET and neurodegeneration in Alzheimer's Disease. Nat Rev Neurol. 2021;17(11):671-684.
7 Rowe CC, et al. Head-to-head comparison of tau PET tracers. J Nucl Med. 2020;61(4):599-605.
8 Ishiki A, et al. Tau PET with second-generation tracers in Alzheimer's Disease. Alzheimers Dement. 2021;17(2):277-288.
9 Gunn RN, et al. Tau PET modelling and quantification. NeuroImage. 2020;224:117403.
10 Baker SL, et al. Quantitative tau PET imaging. NeuroImage. 2017;158:479-488.